FDA Expands LifeStent Use to Longer SFA Lesions

 

January 27, 2011

The U.S. Food and Drug Administration (FDA) expanded the indication for the Bard Peripheral Vascular LifeStent and LifeStent XL nitinol self-expanding stents for the treatment of lesions up 240 mm in length.

The stents are now indicated are intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in native superficial femoral artery (SFA) and/or proximal popliteal arteries with reference vessel diameters ranging from 4 to 6.5 mm.

The stents were originally cleared in February 2009 for the treatment of lesions up to 160 mm in length. The stents are equivalent in design with only one difference located at the crown section. The LifeStent stent has six tantalum radiopaque markers on both the distal and proximal ends of the stent, while the LifeStent XL stent does not have markers.

The expanded indication was granted in December 2010.

For more information: www.bardpv.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.